What were the key findings of the Phase III CARES trials of anselamimab, an anti-fibril antibody, combined with plasma cell-directed therapy in newly diagnosed AL amyloidosis?
The primary endpoint was met in the overall population, with the greatest benefit in patients with lambda light-chain disease.
The primary endpoint was not met in the overall population, but a strong signal of benefit in all-cause mortality and cardiac-related hospitalizations was seen in patients with kappa light-chain disease.
The primary endpoint was not met, and no benefit was seen in any subgroup, so development of the antibody was stopped.